Breadcrumb Navigation

Melanom: A Phase 3, Randomized, Open-label Study of Bempegaldesleukin (a modified Interleukin-2) combined with Nivolumab (anti-PD-1 Monoclonal Antibody) versus Nivolumab in Participants with previously Untreated Unresectable or Metastatic Melanoma

Stadium/Indikation inkl. Kurzinfo

Melanom – 1st line

Stadium III oder IV
Anti-PD1 + modified IL12 vs Anti-PD1

Kurztitel

BMS CA045-001
NCT03635983

Offizieller Titel

A Phase 3, Randomized, Open-label Study of Bempegaldesleukin (a modified Interleukin-2) combined with Nivolumab (anti-PD-1 Monoclonal Antibody) versus Nivolumab in Participants with previously Untreated Unresectable or Metastatic Melanoma

PI

Prof. Reinhard Dummer

Zuständige Ärztin

Simona Steinmann

Tel. +41 43 253 87 57

Zuständiger Arzt

Dario Simic

Tel. +41 43 253 23 35

Behandelnder Fachbereich

Dermatologische Klinik